Nye behandlingsmuligheder ved primær immun trombocytopeni

Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, Claus Henrik Nielsen, Ove Juul Nielsen, Jesper Stentoft, Hans Carl Hasselbalch

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind173
Udgave nummer4
Sider (fra-til)271-4
Antal sider4
ISSN0041-5782
StatusUdgivet - 2011

    Fingerprint

Emneord

  • Antibodies, Monoclonal, Murine-Derived
  • Benzoic Acids
  • Dexamethasone
  • Glucocorticoids
  • Humans
  • Hydrazines
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Prednisolone
  • Purpura, Thrombocytopenic, Idiopathic
  • Pyrazoles
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Splenectomy
  • Thrombopoietin

Citationsformater

Gudbrandsdottir, S., Frederiksen, H., Birgens, H. S., Nielsen, C. H., Nielsen, O. J., Stentoft, J., & Hasselbalch, H. C. (2011). Nye behandlingsmuligheder ved primær immun trombocytopeni. Ugeskrift for Laeger, 173(4), 271-4.